Court settlement opens U.S. market to Teva

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Teva Pharmaceutical Industries, a generic drug manufacturer, has settled in district court on confidential terms, that allow Teva to license three generic oral tablet versions in the U.S. market by the first quarter of 2012.

The settled court case includes the generic versions of GlaxoSmithKline’s Avandia, called Rosiglitazone Maleate; Avandamet, called Rosiglitazone Maleate/Metformin HCl; and Avandaryl, called Rosiglitazone Maleate/Glimepiride, according to the Tikva, Israeli-based Teva.